Pharmigene, Inc. (TPEX:7595)

Market Cap	623.24M
Revenue (ttm)	149.25M
Net Income (ttm)	-75.51M
Shares Out	50.47M
EPS (ttm)	-1.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	6,000
Average Volume	60,848
Open	12.30
Previous Close	12.20
Day's Range	12.30 - 12.35
52-Week Range	9.88 - 16.70
Beta	0.11
RSI	54.02
Earnings Date	Nov 11, 2025

About Pharmigene

Pharmigene, Inc. designs, develops, manufactures, and sells diagnostic tests in Taiwan and internationally. It offers molecular diagnostics to test adverse drug reactions; and DNA extraction products for gene expression analysis, clinical molecular diagnosis, human identity testing, forensics, and biomedical research applications. The company also provides pharmacogenomics test, drug allergy test, and functional medicine test services. In addition, it distributes various genomics and genetics equipment and reagents; and provides professional co...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1994
• Employees: 42
• Stock Exchange: Taipei Exchange
• Ticker Symbol: 7595

Financial Performance

In 2024, Pharmigene's revenue was 116.53 million, a decrease of -12.19% compared to the previous year's 132.71 million. Losses were -82.86 million, 14.1% more than in 2023.